Drug Type Bispecific antibody |
Synonyms AHA1031 |
Target |
Action inhibitors |
Mechanism MICA inhibitors(MHC class I polypeptide-related sequence A inhibitors), MICB inhibitors(MHC class I polypeptide-related sequence B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| STK11 Mutation Non-Small Cell Lung Cancer | Preclinical | United States | 06 Jan 2025 | |
| STK11 Mutation Non-Small Cell Lung Cancer | Preclinical | United States | 06 Jan 2025 | |
| STK11 Mutation Non-Small Cell Lung Cancer | Preclinical | United States | 06 Jan 2025 |






